Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance

Biogen IncTrade
Invesco WilderHill Clean Energy ETFTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Invesco WilderHill Clean Energy ETF — how do they compare? Biogen Inc trades at $202.7 (market cap $30.60B), while Invesco WilderHill Clean Energy ETF trades at $34.96. The key difference: Biogen Inc is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.

BIIBPBW
Market Cap
$30.60B
Sector
HealthSector/Thematic
52-Week High
$216.63$46.99
52-Week Low
$128.93$24.14
Enterprise Value
$37.67B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

No Aura AI signal available yet.

Invesco WilderHill Clean Energy ETF

PBW trades at $34.81, up 3.48% today, with a neutral technical signal and mixed moving averages. The clean energy ETF shows strength amid sector tailwinds from geopolitical tensions and data center demand, though it faces volatility from interest rate sensitivity. A dividend of $0.24 is scheduled for June 2026, but key valuation ratios like P/E and P/S are unavailable in the data.

The outlook hinges on clean energy adoption trends and Federal Reserve policy, with opportunities in global investment shifts but risks from rate cycles and oil price swings. Analyst sentiment is divided, reflecting the ETF's exposure to macroeconomic factors over company-specific fundamentals.

Returns comparison

Trailing returns across standard periods

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About Invesco WilderHill Clean Energy ETF

PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.

Read more on PBW